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Recent studies indicate that DNA methylation can be used to identify transcriptional enhancers, but no systematic
approach has been developed for genome-wide identification and analysis of enhancers based on DNA methylation.
We describe ELMER (Enhancer Linking by Methylation/Expression Relationships), an R-based tool that uses DNA
methylation to identify enhancers and correlates enhancer state with expression of nearby genes to identify
transcriptional targets. Transcription factor motif analysis of enhancers is coupled with expression analysis of
transcription factors to infer upstream regulators. Using ELMER, we investigated more than 2,000 tumor samples
from The Cancer Genome Atlas. We identified networks regulated by known cancer drivers such as GATA3 and
FOXA1 (breast cancer), SOX17 and FOXA2 (endometrial cancer), and NFE2L2, SOX2, and TP63 (squamous cell lung
cancer). We also identified novel networks with prognostic associations, including RUNX1 in kidney cancer. We
propose ELMER as a powerful new paradigm for understanding the cis-regulatory interface between cancer-associated
transcription factors and their functional target genes.Background
ENCODE and other large-scale efforts have mapped
transcription factor binding sites, histone modifications,
and chromatin accessibility in a common set of cell lines
[1, 2]. Integration of these genome-wide maps has led to
the view that distinct epigenetic marks are not inde-
pendent but rather that chromatin is organized into
discrete functional states marked by particular combina-
tions of individual features [3, 4]. Computational
methods such as chromHMM [5] and Segway [6] have
been developed to identify these states from individual
histone and accessibility features, and the state most
consistently linked to cellular identity is the ‘active enhan-
cer’ state defined by the presence of histone H3 lysine 27
acetylation and low levels of the canonical promoter mark,
H3 lysine 4 tri-methylation [5, 7, 8]. Active enhancers are
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creativecommons.org/publicdomain/zero/1.0/transcription factors, reinforcing their preeminent role in
encoding the cis-regulatory logic of the genome. Projects
such as the NIH Roadmap [2, 9] and Blueprint [10] have
also mapped histone modifications and chromatin accessi-
bility in primary human tissues, identifying a large set of
enhancers from many different cell types. Others have
employed these datasets to identify large numbers of
enhancer-promoter pairs in 12 human cell types [11, 12].
However, approaches such as ChIP-seq or DNAse hyper-
sensitivity assays require careful tissue handling (to avoid
protein degradation) and relatively large numbers of cells
(106 to 107) and thus have not been applied to the identifi-
cation of enhancers in primary tumor tissues.
Fortunately, enhancers can also be identified using pat-
terns of 5-methylcytosine, an epigenetic mark that is
maintained more stably than protein marks, and can be
detected genome-wide in as few as 1,000 cells [13]. His-
torically, DNA methylation research has focused on gene
promoter regions (reviewed in [14]). While early work
suggested that DNA methylation could mark enhancer
regions of interest [15], this was not widely appreciated
until the first complete and unbiased study of DNA
methylation in human cells revealed enhancer regions as
being unmethylated in a cell-type specific manner [16].
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gions containing little or no methylation; these regions
overwhelmingly corresponded to enhancers and other
distal regulatory elements [17]. Cell-type specific de-
methylation of enhancers was confirmed by targeted bi-
sulfite sequencing in the ENCODE project [1]. More
recently, WGBS data from 30 diverse human cell types
showed that enhancers had highly dynamic methylation
patterns - roughly 30% of the most cell type-specific re-
gions in the genome overlapped known enhancers (com-
pared to 5% that overlapped gene promoters). The
mechanism underlying these correlations is not well
understood, but could involve de-methylation of DNA
initiated by transcription factor binding ([17]; reviewed
in [18]) and maintained by DNA methyltransferase pro-
tection by Histone H3 lysine 4 monomethyl groups [19].
In cancer tissues, recent studies have shown that
cancer-specific enhancers and transcription factor bind-
ing sites can be identified from DNA methylation pro-
files. The first genome-scale analysis of transcription
factor binding sites in cancer found that binding by tran-
scription factors such as Sp1, NRF1, and YY1 could pro-
tect CpG island gene promoters from cancer-specific
hypermethylation [20]. Our WGBS study of a human
colon cancer identified all genomic regions that changed
from a methylated state in the normal colon to an
unmethylated state in the tumor; 90% of these regions
overlapped known enhancers, and a highly dispropor-
tionate number contained binding sites for the AP-1
transcription factor [21]. A more recent study showed that
DNA methylation changes at enhancer elements were sig-
nificantly better than those at promoters for predicting
gene expression changes of target genes in cancer [22].
WGBS was recently used to show that unmethylated re-
gions were enriched for binding sites for subtype-specific
transcription factors in pediatric medulloblastoma (LEF1
for the WNT subtype and GLI2 for the SHH subtype [23]).
Once an enhancer has been identified by DNA methy-
lation, identification of the specific target gene or genes
whose expression is modulated by that enhancer can be
challenging because the target genes can be thousands
to millions of base pairs away from the enhancer. A
study using chromatin conformation sequencing (ChIA-
PET) to study enhancer/promoter interactions found
that the median distance between an enhancer and a
promoter was approximately 50 kb, and that at least 40
% of enhancers skip one or more annotated genes to find
their target promoter [24]. The ChIA-PET dataset was
used in conjunction with DNA methylation and RNA-
seq data from breast cancer cases in The Cancer Gen-
ome Atlas (TCGA) to identify enhancer/promoter pairs
in vivo [25]. Other reports have also shown that methy-
lation of distal regulatory sites is closely related to gene
expression levels across the genome [26]. Here, wepresent a statistical framework for identification of
cancer-specific enhancers and paired gene promoters,
and use it to investigate approximately 3,000 cases from
11 tumors types in the TCGA ‘Pan Cancer’ analysis set
[27]. Our R software package, ELMER, uses only methy-
lation and expression data, and does not require any
chromatin conformation or ChIP-seq data. Furthermore,
by identifying transcription factor binding motifs present
within enhancers, and incorporating expression patterns
of upstream transcription factors, ELMER is able to infer
transcription factor networks activated in specific cancer
subtypes. This work suggests a general approach for iden-
tifying in vivo transcription factor networks and the asso-
ciated regulatory control sequences altered in cancer.
Results
Identifying cancer-specific DNA methylation changes in
distal enhancer regions for 10 cancer types
To identify cancer-specific changes in DNA methylation,
we obtained 3,381 DNA methylation datasets for 11
types of primary tumors from the TCGA Pan Cancer
analysis set [27]. The cancer types we included in our
analyses were leukemia (LAML), lung adenocarcinoma
(LUAD), lung squamous cell carcinoma (LUSC), kidney
renal clear cell carcinoma (KIRC), bladder urothelial car-
cinoma (BLCA), uterine corpus endometrioid carcinoma
(UCEC), glioblastoma (GBM), head and neck squamous
cell carcinoma (HNSC), breast cancer (BRCA), colon
adenocarcinoma (COAD), and rectal adenocarcinoma
(READ). Based on previous TCGA studies [28], COAD
and READ are very similar and are often combined for
analyses. Therefore we combined these two cancer types
(indicated herein as CRC), resulting in 10 different pri-
mary tumor types. The TCGA ID numbers for all sam-
ples can be found in Additional file 1.
The DNA methylation datasets were produced using
the Illumina Infinium HumanMethylation450 (HM450)
BeadChip platform. The HM450 array allows the inte-
gration of more than 485,000 methylation sites at single-
nucleotide resolution, covering 96 % of CpG islands and
99 % of RefSeq genes in the human genome. We used
TCGA Level 3 data, which are normalized using
platform-specific internal controls, and mask out probes
for failure/SNP/repeats on the HumanMethylation450
array. Then, because we focused on distal enhancers, we
selected only those probes that are greater than +/- 2 kb
from a known TSS (defined using GENCODE v15 [29],
resulting in a set of 145,265 distal probes. We next
wanted to limit the number of candidate probes tested,
so we filtered based on two large enhancer databases.
While these databases do not include a large number of
primary tumors, they do include cancer cell lines and a
large number of cell types. The largest enhancer set
came from a combination of enhancers from the
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the Encyclopedia of DNA Elements (ENCODE) Project, in
which enhancers were identified using ChromHMM [30]
for 98 tissues or cell lines [2, 9, 31]. We used the union of
genomic elements labeled as EnhG1, EnhG2, EnhA1, or
EnhA2 (representing intergenic and intragenic active en-
hancers) in any of the 98 cell types, resulting in a total of
389,967 non-overlapping enhancer regions. A total of
101,918 distal probes from the HM450 array overlapped
with these enhancer regions. We also downloaded from
FANTOM5 enhancers having associated eRNAs for 400
distinct cell types [32]. The set of FANTOM5 enhancers
(43,011) was much smaller than the set of REMC/EN-
CODE enhancers and only added an additional 600
probes, resulting in a total of 102,518 distal probe re-
gions that overlapped with a previously identified en-
hancer region (Fig. 1a). This set of 102,518 distalFig. 1 Identifying cancer-specific DNA methylation changes in distal enhan
102,518 were contained within our annotated enhancer regions (with appr
probe). b The statistical method used to identify probes hypomethylated (o
heatmap in the top panel shows the DNA methylation level at each probe
normal, or a tumor). Each cell is a methylation β value, reflecting the fractio
the panel illustrates our statistical test, which compares only the most extrem
in order to identify probes hypomethylated in only a subset of tumors. (c
hypomethylated (top graph) or hypermethylated (bottom graph) distal e
probes shared by one or more other tumor types is indicated by the colo
tumor type, 2 indicates that it is hypomethylated in one other tumor typenhancer probes (Additional file 2) included at least
one CpG for 15 % of all enhancers in our annotation
set, suggesting that the HM450k array can be used to
sample a meaningful subset of enhancers genome-wide.
It also included the majority (70 %) of all 145,265 distal
probes on the array, so we believe that the analysis de-
scribed below covers the vast majority of identifiable
enhancers based on the HM450k array design. The
ELMER R package also allows a complete search of all
distal probes on the array, without filtering out the 30 %
not associated with any known enhancer.
To identify enhancers that displayed cancer-specific
changes in DNA methylation, we applied a t-test to
identify enhancer probes that were significantly hyper-
methylated or hypomethylated within tumor samples of
each cancer type, relative to TCGA adjacent normal
samples from the same tissue (Fig. 1b; see Methods forcer regions. a Out of 145,265 distal probes on the HM450k platform,
oximately 1/8 of all distal enhancers being covered by at least one
r hypermethylated) in cancer (see Methods for additional details). The
pi for each sample from a particular cancer type (either an adjacent
n of methylated DNA molecules at each CpG probe. The remainder of
e 20 % of normal samples to the most extreme 20 % of tumor samples,
) Shown is a histogram representing the number of cancer-specific
nhancer probes identified for each cancer type. The fraction of these
r bars (1 indicates that the probe is hypomethylated in only that
e, and so on)
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methylated enhancer probes for each tumor type can be
found in Additional file 3. We identified many more
hypomethylated enhancer probes than hypermethylated
probes for each of the 10 cancer types (Fig. 1c). Interest-
ingly, most of the probes showing DNA methylation
changes were found to have similar changes in DNA
methylation in more than one cancer type. However,
some probes were uniquely hypermethylated or hypo-
methylated in only one of the 10 tumor types. We note
that it is not possible for us to be certain that the adja-
cent tissues collected by TCGA correspond to the same
cell type from which the cancer arose, and therefore
some of these methylation changes may correspond to
tissue-specific differences rather than changes arising in
the cancer. However, these differentially methylated
probes are only candidates, as the next steps of ELMER
(described below) use differences across all normal and
tumor tissues (of the same cancer type) to determine
true regulatory interactions.
Linking methylation-affected enhancers to gene
expression
Although we identified approximately 100,000 enhancer
probes that showed DNA methylation changes, it was
not clear if all of these enhancers were actually involved
in regulating gene expression. Previous studies have
shown that only a portion of genomic regions classified
as enhancers by chromatin marks or recruitment of his-
tone acetyltransferases show activity in various assays
[33, 34]. In addition, it is difficult to know which gene is
regulated by each enhancer since enhancers can work
from a distance, in either orientation, and do not neces-
sarily regulate the closest gene. For example, in a ChIA-
PET study using an antibody for RNA polymerase II, Li
et al. [24] identified approximately 20,000 to 30,000
enhancer-promoter loops in MCF7 or K562 cells. Of
these, more than 40 % of the enhancers skipped over the
nearest gene to loop to a farther one. In order to identify
target genes regulated by the distal regulatory elements,
we analyzed expression data (RNA-seq) for 10 genes up-
stream and 10 genes downstream from each distal regu-
latory element; these 20 nearby genes constituted
candidate gene targets. We preferred this method rather
than those that evaluate all genes within a fixed-length
genomic window, because the statistical power is con-
trolled for the large degree in variation in gene density
across the genome. Because not all TCGA samples had
matched gene expression datasets, we selected the 2,841
TCGA samples that had matched gene expression
(RNA-seq) and HM450k DNA methylation data (in
Additional file 1). Although we realize that this method
cannot identify target genes that are farther than ten
genes away or on different chromosomes, we anticipatedthat many of the enhancers would regulate a gene within
this distance [5]. Genes that are positively regulated by
the enhancers should show a negative correlation between
the DNA methylation level of the probe and expression of
a putative target gene. We identified statistically signifi-
cant CpG probe-gene pairs by comparing expression of
the candidate gene in the upper vs. the lower quintile of
samples, as measured by enhancer probe methylation. For
this and all other downstream analyses, we included both
normal and tumor samples, and only included samples
within an individual cancer type (for example, UCEC), to
avoid effects of tissue-specific differences and potential
batch effects. We did not explicitly require expression
changes between normal and tumor samples, because the
number of normal samples with expression data were
often quite limited. However, most genes identified did in
fact show expression changes in the expected direction
(downregulated for hypermethylated enhancers, and up-
regulated for hypomethylated enhancers; see the ‘tumor
vs. normal expression’ worksheet in Additional file 4). To
compare methylation quintiles vs. expression, we used a
non-parametric U test, calculating an empirical P value
using randomly assigned permutations of the methylation
probe tested, and kept all pairs with an empirical P value
<0.001 (Fig. 2a; see Methods for details). An example of
one probe and its relationship to the expression of the 20
nearby genes in UCEC is shown in Fig. 2b. In this case,
the probe showed an inverse correlation of methylation
with expression of TFAP2A, which was the nearest gene
upstream of the probe (approximately 7 kb away). A list of
all putative enhancer-gene interactions can be found in
Additional file 4.
Using this method, we identified a total of 11,972
hypomethylated probe-gene pairs and 2,308 hyper-
methylated probe-gene pairs in the set of 10 tumor types
(Fig. 3a), with the number of hypomethylated probe-
gene pairs ranging from 499 to 3,847 in different tumor
types, and the number of hypermethylated probe-gene
pairs ranging from 119 to 464 (see Additional file 5 for a
breakdown by type). Analysis of the probe-gene pairs re-
vealed that most of the identified pairs were only found
in one cancer type, suggesting that each enhancer regu-
lates a specific gene in a tumor type-specific manner
(Fig. 3a). Because some enhancers contained two or
more probe features, we clustered probes that were
within 500 bp of each other into 6,068 hypomethylated
and 1,288 hypermethylated enhancer regions. Each en-
hancer was associated with an average of 1.0 to 1.7
genes, depending on tumor type, and each gene was as-
sociated with an average of 1.2 to 2.1 enhancers (Fig. 3b).
Our work is consistent with previous studies indicating
that distal elements commonly loop to or are associated
with expression from 1 to 3 promoters [35]. Although
the enhancer-gene pairs that we identified were highly
Fig. 2 Linking differentially methylated probes to expression of nearby genes. a Shown is an illustration of the method used to associate each
differentially methylated enhancer probe with one or more genes based on gene expression (see Methods section for additional details). For
each of n probes identified as hypomethylated in a given cancer type (shown as blue circles), 10 genes upstream and 10 genes downstream
were considered, yielding 20n statistical tests, one for each probe-gene pair. Each statistical test is performed across the complete set of normal
and tumor samples within a particular cancer type. For instance, we show a scatterplot to illustrate such a test across the 258 endometrial (UCEC)
tumor samples and 10 UCEC adjacent normals, showing the desired inverse correlation between methylation (x axis) and expression of the
nearby gene (y axis). A Mann-Whitney U test was then performed, with the null hypothesis that the gene expression of group M samples is less
or equal to that of group U samples. The U group consists of the 20 % least methylated samples for probe Pi, and the M group consists of the
top 20 % most methylated. The raw P value (pr) was compared to a permutation-based distribution of null P values, generated by performing
10,000 U tests between the actual gene Gj and DNA methylation a randomly selected distal non-enhancer probe. The empirical pe value was
calculated by the rank of pr within the 10,000 trials. b Each scatter plot shows the methylation level of an example probe cg09606832 in all UCEC
samples plotted against the expression of one of 20 adjacent genes. Only one gene, TFAP2A, shows a significant pe indicating negative correlation,
and is considered the linked gene
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mately 34 % of the genes identified as regulated by a
hypomethylated probe and approximately 17 % of the
genes identified as regulated by a hypermethylated probe
were targets in more than one tumor type (Fig. 3a), sug-
gesting that a gene could utilize different enhancers in
different tumor types for cancer-specific regulation.
To further investigate the relationships between puta-
tive enhancers and linked target genes, we determined
the frequency with which the probe-gene pairs we iden-
tified were separated by specific distances using window
sizes of 50 or 200 kb (Fig. 4a). We found that both hypo-
methylated and hypermethylated probe-gene pairs were
more frequent than random in the first 50 kb window,
with hypermethylated pairs more dramatically so. A pre-
vious study using HiC to identify promoter-enhancer
loops found that approximately 25 % of enhancer-
promoter pairs were within a 50 kb range andapproximately 75 % spanned 100 kb or larger genomic
distance, with a median distance of 124 kb [36], whereas
a recent study using in situ HiC identified contact do-
mains ranging in size from 40 kb to 3 Mb, with a me-
dian size of 185 kb [37]. We then selected the set of
probe-gene pairs where a single enhancer was only
linked to a single gene (the great majority), and deter-
mined how often the linked gene corresponded to the
nearest TSS. In previous studies, enhancers have been
shown to loop to the nearest promoter only 27 % to 40
% of the time, skipping over the nearest TSS to loop to
promoters farther away [24, 35]. We found that only ap-
proximately 15 % to 30 % of the time did the correlated
gene correspond to the nearest TSS, with the percentage
being higher for hypermethylated probe-gene pairs than
for hypomethylated probe-gene pairs (Fig. 4b). This was
significantly higher than the frequency of an enhancer
being linked any other farther away gene (4 % to 8 %);
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link to the nearest gene, the disproportional number of
first-gene linkages gave us confidence that many or most
of our linkages were true cis-regulatory links, including
those that linked to more distant genes. If the linked
gene did not correspond to the nearest TSS, there was
very little preference to link to a nearby gene; the one
exception was that hypermethylated enhancers were
more likely to link to either the closest or second closest
gene. This analysis is shown individually for each of the
10 tumor types in Additional file 6.
As indicated above, many of the genes that we identi-
fied as linked to enhancers with cancer-associated DNA
methylation differences were actually identified in more
than one cancer type, suggesting that they may have
some common function in tumor initiation or progres-
sion. We selected all genes linked to an enhancer probe
in more than one cancer type and performed a Gene
Ontology enrichment analysis (Fig. 5). The 1,959 genes
linked to hypomethylated (activated) enhancer probes
correspond to genes upregulated in cancer, and the 284
genes linked to hypermethylated (inactivated) probes cor-
respond to genes downregulated in cancer. Interestingly,
we found that genes linked to hypermethylated (inacti-
vated) enhancers were genes involved in development and
differentiation. In contrast, genes linked to hypomethy-
lated (activated) enhancers were classified as involved in
the cell cycle and other cellular processes. Accordingly, we
have identified known tumor suppressors (for example,
TSG1, RBM6, SPRY2, CDKN1A, and UBE4B) in the set of
genes potentially regulated by the hypermethylated en-
hancers and known oncogenes and cancer-associated
genes (for example, MYC, TERT, ERBB3, ERBB4, FGFR3,
VEGFA, CDK7, and CCND1) in the set of genes poten-
tially regulated by the hypomethylated enhancers.
Identification of regulatory TFs in each cancer type
Changes in methylation status of an enhancer region can
be due to gain (for hypomethyated enhancers) or loss
(for hypermethylated enhancers) of site-specific tran-
scription factors. To obtain insight into which site-
specific TFs may be involved in setting the tumor-
specific DNA methylation patterns, we examined the
correspondence between cancer-specific hypermethy-
lated or hypomethylated probes and known regulatory
factor recognition sequence motifs. We used a combined
set of motifs present in the JASPAR-Core [38] and Fac-
torBook [39] datasets. We selected the enhancer probes
that were identified in probe-gene pairs (using a cutoff
of 0.001), then used the +/-100 bp sequence around each
probe to search for instances of the 145 transcription
factor motifs. We calculated the frequency of each motif
within the hypomethylated (or hypermethylated) probe
set for a given cancer vs. the frequency of the motifwithin the entire enhancer probe set. An odds ratio
(OR) was calculated from these two frequencies, and
only those motifs with an OR greater than 1.1 (at a con-
fidence interval of 95 %) were selected as enriched
within the given cancer type (motifs with less than 10 in-
stances within the given probe set were excluded). All
enriched motifs are listed in Additional file 7. For hyper-
methylated loci, we found that many of the identified
motifs (such as E2F, EGR1, NRF1, Sp1) were associated
with promoter regions (Additional file 8), suggesting that
many of the hypermethylated loci may actually corres-
pond to previously uncharacterized promoter regions.
This likely accounts for the relatively high percentage of
hypermethylated probe-pairs that showed linkage to the
nearest annotated gene (Fig. 4b), which could reflect
RNA-seq tags from the unannotated transcript isoform.
Because many of the hypermethylated cases might not
represent true distal enhancers, and because some may
in fact be the result of cancer-related CpG Island pro-
moter hypermethylation [14], we focused the remaining
analyses on the 38 motifs found to be enriched within hypo-
methylated loci (Fig. 6a). Some of these motifs were com-
mon to various different cancers, such as AP1, which was
enriched within nine of the 10 cancer types. Many motifs
were more enriched in two or more specific tumor types,
while others were limited to a single type, such as of GATA
in BRCA, TP53/TP63 in LUSC, and HNF1A/B in UCEC.
Different members of a TF family have very similar
DNA binding domains that can bind very similar or
identical motifs. For example, we have previously shown
that GATA1 and GATA2 bind to the same regulatory re-
gions [40] and that members of the E2F family can bind
to the same promoters [41]. Thus, identification of a
motif does not uniquely identify the TF that binds
in vivo to a region containing that motif. However, there
is evidence to support the hypothesis that expression
levels of a particular TF can correlate with levels of de-
methylation and subsequent gene expression [18, 42, 43].
To discover which members of a TF family are likely to be
responsible for binding in vivo to the hypomethylated en-
hancer probes identified above and regulating expression
of their putative target genes, we analyzed the correlation
between the probes containing a particular motif and ex-
pression of all known TFs (Fig. 6b, left). We ranked all the
TFs by the degree to which their expression inversely cor-
related with the methylation status of the enhancers con-
taining the motif (Fig. 6b, right), which allowed us to
determine the family member most likely to be involved
in regulation of the putative target genes in that particular
cancer. For example, the GATA motif was enriched in (ex-
pression-linked) enhancer probes in BRCA samples
(Fig. 6a). There are six members of the GATA family, with
different members being linked to different differentiation
phenotypes. For example, GATA1–3 have been linked to
Fig. 3 Comparison of probe-gene pairs between the different cancer types. a For the hypomethylated (top) and hypermethylated (bottom)
probe-gene pairs, shown are pie charts that indicate the percentage of probe-gene pairs, probes, and genes that are present in one (purple) or
shared by more than one of the 10 cancer types. b Using all probe-gene pairs, the distribution of the number of genes per enhancer (top) and the
number of enhancers per gene (bottom) is shown for each individual cancer type. The mean of each is shown as a number within the bar plot
Fig. 4 Physical characteristics of the probe-gene pairs. a A histogram of probe-gene distances for all pairs with a hypomethylated (green) or
hypermethylated (yellow) probe. Shown is the distribution of the distance between linked distal enhancer probes and genes. The X-axis shows
distances in bins of 50 kb or 200 kb. The Y-axis shows the proportion of all probe-gene pairs in the category (hyper- or hypomethylated) that fall
into each range. These were compared to randomized datasets (gray bars), which were generated by randomly selecting 1,000 probes from the
full set of 145,265 distal probes, and randomly pairing each with one of its 20 adjacent genes. We generated 1,000 such datasets to generate 95
% confidence intervals for each bin (+/-1.96* SD). b For each probe in a probe-gene pair, the 20 adjacent genes were ranked by distance, and
shown is the proportion of all probes linked to genes of a given rank. For this analysis, probes linked to more than one gene and multiple probes
linked to the same gene, were omitted
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Fig. 5 Gene Ontology (GO) enrichment analysis for genes identified in more than one cancer type. All genes identified in more than one cancer
type by probe-gene pairs were analyzed for enrichment in particular GO categories, using the TopGO program. Activated genes (associated with
hypomethylated enhancer probes) are shown in (a) and inactivated genes (associated with hypermethylated enhancer probes) are shown in (b).
All GO categories with an adjusted enrichment P value of less than 0.01 (indicated next to the category name) and fold change more than 1.5
are included in the figure, and categories within the same biological process (color) are ordered by enrichment fold change (shown on the x axis).
The adjusted enrichment P values are labeled in white in the graph
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GATA4–6 are involved in differentiation of cardiac and
lung tissues [44–49]. GATA3 is one of the most highly
enriched transcription factors in the mammary epithe-
lium, has been shown to be necessary for mammary cell
differentiation, and is specifically required to maintain the
luminal cell fate [48, 49]. Studies of human breast cancers
have shown that GATA3 is expressed in early stage, well-
differentiated tumors but not in advanced invasive can-
cers. In addition, GATA3 expression is correlated with
longer disease-free survival and evidence suggests that it
can prevent or reverse the epithelial to mesenchymal tran-
sition that is characteristic of cancer metastasis [50]. Not
surprisingly, our analysis of the correlation of the methyla-
tion of the GATA motif-containing hypomethylated
probes identified GATA3 as the most likely member of
the GATA family to be responsible for the observed hy-
pomethylation of GATA-containing enhancers in the
BRCA samples (Fig. 6b). Not only was GATA3 the sec-
ond most correlated transcription factor overall, but
the extent of correlation made it easily distinguishable
from other members (GATA3 had a U test P value less
than 10−40, vs. P values greater than 10−5 for all other
GATA family members). Furthermore, expression of
GATA3 and methylation of GATA-containing enhancer
probes were co-linked to breast cancer subtypes. As
shown using color-coding in the Fig. 6b scatterplot, Lu-
minal tumors had high expression of GATA3 and low
methylation of GATA-containing enhancer probes,
while Basal-like subtype tumors showed the converse.
Figure 6c shows an example of one of these GATA-
containing enhancer probes (cg1396202), along with
the target gene (CCND1) predicted by expression to be
regulated by this putative enhancer. ENCODE ChIP-
seq data in the Luminal-subtype MCF7 cell line con-
firm that this putative enhancer region is indeed bound
by GATA3, confirming the relationship between tran-
scription factor binding and demethylation shown in
[25]. This case was among the easier to detect, since
breast cancer has two large subtypes (Luminal and
Basal-like), which are molecularly quite distinct and are
increasingly seen as two different diseases. As with all
cancer genomic approaches, rarer subtypes will require
larger number of samples to be identified by ELMER.
Nevertheless, our results on other more challenging
cancer types were also promising, as described below.The same correlation analysis was performed for all
motifs enriched in hypomethylated enhancer probes,
and the most highly correlated member of the TF
family expected to bind to each motif was identified
(Additional files 9 and 10). In all, we identified 38
enhancer-TF pairs in the 10 tumor types. Although
some of these TFs have previously been implicated in
tumor development in the cancer type in which they
were identified (for example, GATA3 in BRCA), many
other associations were novel and provide new hy-
potheses regarding basic cancer biology and new po-
tential targets for cancer prevention and treatment. In
order to investigate potential clinical relevance of the
new TF networks identified, we searched for cases
where the TF found to be overexpressed in a subset of
cases was also linked to patient survival. Our TF fam-
ily member analysis showed that RUNX1, RUNX2,
and RUNX3 were all within the top 5 % of TFs corre-
lated with hypomethylation of RUNX-containing en-
hancer probes in clear cell renal carcinoma (KIRC)
(Fig. 7)a, b. Of these, RUNX1 and RUNX2 were very
highly correlated, with RUNX3 being only moderately
so (Fig. 7)a, b. When we investigated patient survival
in KIRC, RUNX1 and RUNX2 had highly significant
associations with poor survival outcome after control-
ling for other co-variates, while RUNX3 was more
marginal (Fig. 7c and Additional file 11A). These re-
sults suggest that the identification of specific TFs
based on enhancer methylation analysis may lead to
new insights into tumor classification and clinical
outcomes (other identified TFs with association to
survival are listed in Additional file 11B).
Discussion
In our studies, we have used tumor-specific changes of
the DNA methylation status within distal enhancer re-
gions to provide insight into the mechanisms of gene ex-
pression, transcription factor networks, and tumor
classification. We have shown that this can be a power-
ful approach for generating hypotheses about master
regulators in cancer, and we propose that ELMER ana-
lysis be applied along with other hypothesis-generating
approaches in high throughput cancer genomics. For the
TCGA Pan-Cancer dataset, we provide to the commu-
nity prioritized lists of putative enhancer-target gene
pairs for future validation, and lists of site-specific
Fig. 6 Identification of enhancer sets predicted to be co-regulated by the same transcription factor. a For 38 motifs enriched within hypomethylated
probe-gene pairs in one or more cancer types, we calculated the 95 % confidence interval (CI) for the motif enrichment odds ratio; the lower bound
of the 95 % CI is shown for each cancer type in the heatmap. b An illustration of the method for linking sets of enhancers with the same motif to an
upstream TF regulator (see Methods for additional details). For each of the 38 (m) enriched motifs identified in panel (a), the average DNA methylation
at all distal enhancer probes having that motif (in a specific tumor type), was compared to the expression levels of each of 1,777 (k) human
TFs (Additional file 17). One such pair is shown as a scatter plot of all breast cancer (BRCA) tumor and adjacent normal samples, for the GATA
motif and the GATA3 TF. BRCA samples (660) are color coded by integrated molecular subtypes defined by the TCGA Pan Cancer project, and
extremes are selected as the 20% of samples with the lowest methylation (U) and the 20% with the highest methylation (M). A Mann-Whitney
U test was performed to obtain the raw P value (pr). All 1,777 TFs were then ranked by pr (plot at upper right), and the top 5% of the ranked
TFs (dashed blue line) were considered to be significantly associated. The top three ranked TFs, along with each member of the specific DNA-
binding family (in this case, GATAs) are labeled. Additional file 10 contains ranked TF plots for all motifs and all cancer types. c One of the 230
hypomethylated probe-gene pairs in BRCA containing a GATA motif corresponds to a downstream enhancer of the CCND1 gene. ENCODE
ChIP-seq data in the Luminal-subtype MCF7 cell line verify that this enhancer is bound by the ELMER-predicted GATA3 TF
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Fig. 7 High RUNX1 expression is associated with poor survival in clear cell renal carcinoma. a Shown are scatter plots for the average DNA
methylation at hypomethylated-paired probes containing a RUNX motif, plotted against expression for RUNX family members RUNX1, RUNX2,
and RUNX3. The number (and percentage) of hypomethylated-paired probes having a RUNX motif in each cancer type is indicated underneath
the name of each cancer type. b The ranked TF plot, as described in Fig. 6, is plotted for the RUNX motif in clear cell renal carcinoma (KIRC);
RUNX1, RUNX2, and RUNX3 are all within the top 5 % (dotted line) of all TFs. (c) Kaplan-Meier survival curves for TCGA KIRC samples, stratified by
expression of RUNX1 (left), RUNX2 (middle), or RUNX3 (right). In each plot, the survival data for patients having tumors with the highest (top 30
%) vs. lowest (bottom 30 %) expression for the given RUNX family member is shown; the Log-Rank test P value between the high and low groups
is indicated
Yao et al. Genome Biology  (2015) 16:105 Page 11 of 21transcription factors that should be further investigated
for their role in the development and progression of spe-
cific tumor types.
Starting with a set of approximately 100,000 distal en-
hancer probes, we identified tens of thousands of enhan-
cer regions that showed changes in methylation status in
primary human tumors (Fig. 8). We identified many
more hypomethylated (ostensibly activated) enhancers
than hypermethylated (ostensibly deactivated) enhancers
and have focused mainly on the hypomethylated en-
hancers in this study. We identified from 5,147 to
26,787 hypomethylated probes in different tumor types,
corresponding to between 4,841 and 21,374 distinct en-
hancer regions. However, only a smaller subset of these
hypomethylated enhancer probes (a total of 6,559 for all
tumor types combined) could be linked to a putativetarget gene (based on expression levels of the 10 nearest
genes upstream and 10 nearest genes downstream of the
enhancer), ranging from a low of approximately 200
enhancer-putative target gene pairs in acute myeloge-
nous leukemia to approximately 4,000 enhancer-putative
gene pairs in lung cell squamous carcinomas. We feel
that the expression filtering step is important for identi-
fying those regions truly associated with enhancer-
specific methylation, as other long-range methylation
changes (such as global hypomethylation [14]) may also
affect enhancer probes.
We found that most of the putative linkages between
enhancer probes and local gene expression were cancer
type-specific and that within each cancer type, most en-
hancers correlated with the expression of only one gene.
In keeping with previous looping studies, we found that
Fig. 8 Identification of in vivo TF networks, including upstream TFs and downstream enhancers and gene targets. The innermost black circle
represents the 102,518 distal enhancer probes from the HM450 platform. The next level (labeled Hypo) shows the number of hypomethylated
distal enhancer probes identified in each cancer type. The third level (labeled Paired hypo) shows the number of hypomethylated probes that
were significantly linked to a putative target gene in each cancer type. The number in the outermost level corresponds to the number of putative
target genes (each linked by expression level to a specific hypomethylated enhancer) predicted to be regulated by the indicated TF (fourth level);
where multiple TF family members were identified, only the most strongly associated family member is listed
Yao et al. Genome Biology  (2015) 16:105 Page 12 of 21the putative target gene was typically not the nearest gene.
In fact, the gene identified was the nearest gene in only
approximately 15 % of the hypomethylated enhancer-gene
pairs. As in other studies [51, 52], we found that the set of
all hypomethylated enhancers was composed of similar
proportions of intragenic and intergenic enhancers. We
found that as compared to the intergenic enhancers, intra-
genic enhancers were 75 % more likely to be linked to ex-
pression of the nearest TSS (which in 88 % of the cases
was the gene in which it resided); see Additional file 12.
An intragenic enhancer can loop to regulate the ‘up-
stream’ promoter of the gene in which it resides but could
also act as alternative promoter. Although we have elimi-
nated all known promoters from our set of distal probes,
we cannot eliminate the possibility that some of the intra-
genic enhancers represent as-of-yet unannotated, tumor-
specific alternative promoters for the gene in which they
reside [53, 54].
Our linking method is based strictly on correlation
and therefore cannot absolutely rule out indirect (trans)interactions. For instance, if the same transcription fac-
tor or set of factors regulate both enhancer X and en-
hancer Y, the methylation patterns of X and Y across
samples may be so similar that we link enhancer X to a
gene that is in fact the direct target of enhancer Y. We
have used high-confidence statistical thresholds in order
to rule out as many of these indirect interactions as pos-
sible. Our search within the nearest 20 genes is un-
biased, so the fact that we disproportionally find linkages
to the gene nearest the enhancer probe provides strong
evidence that we are identifying true direct (cis) interac-
tions. We have provided a robust set of predicted link-
ages that can serve as a starting point for future
experimental validations. Of course, we realize that we
are working under a largely untested assumption that
anti-correlation between an enhancer and expression
level of a nearby gene indicate functional regulation.
While this and prior correlative studies [22, 23, 25] pro-
vide strong supporting evidence for this, further experi-
mental studies (for example, using CRISPR/Cas9 to
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followed by RNA-seq) will be needed to determine with
certainty that the enhancers regulate their putative target
genes, and what degree of correlation is required to infer
functionality. Similarly, a comparison between our pre-
dicted enhancer-target pairs and global analysis of long-
range chromatin looping would be of interest. Unfortu-
nately, chromatin conformation assay data are not avail-
able for any of the tumor tissue samples and, in fact,
very few studies of global chromatin looping have been
completed for cancer cell lines. However, we have identi-
fied a set of chromatin loops derived from deep-sequenced
ChIA-PET data from MCF7 cells [24]. Although MCF7
cells are not representative of all breast cancers (and are
cultured cells, not tumor tissues), we did find that 166 of
the 2,038 enhancer probes pairs we identified in breast
cancer tumors (approximately 8%) were also identified as
loops in the MCF7 ChIA-PET data. This was an almost
four-fold enrichment over randomized enhancer probe-
gene pairs (see Additional file 13 for an enrichment ana-
lysis, along with a complete list of BRCA enhancer-gene
pairs falling within loops in MCF7 cells). We note that the
various assays used to study looping are not yet optimized
and do not always identify the same sets of loops [55]; in
addition, some loops may not be related to transcriptional
regulation. Thus, enhancer-gene pairs identified by expres-
sion assays are not necessarily concordant with the sets of
promoter-enhancer loops identified by chromatin confirm-
ation assays. Future comparisons between indirect (that is,
correlative) mapping of enhancer-gene interactions of the
type we described here, with direct physical mapping of
enhancer-gene interactions, will be important to help to re-
solve the different mechanisms involved. However, in
addition to the genome-wide confirmation by ChIA-PET,
we note that at least two of the putative enhancer-gene
pairs from our analysis have been studied in functional
models confirming our results. The putative CCND1 en-
hancer we identified in breast tumors (Fig. 6c) was shown
to directly regulate the CCND1 gene in response to estra-
diol in breast cancer cells [56] and a putative MYC enhan-
cer we identified in colon tumors (Additional file 14) was
shown to be directly responsible for MYC expression in
colon cancer cells [57], and in vivo in a mouse model of
colorectal cancer [58].
We realize that the relationship between TF binding
and DNA methylation can be complex [18]. For ex-
ample, reduced DNA methylation in an enhancer region
in a tumor cell relative to a normal cell could allow a TF
to bind and regulate a target gene in a tumor-specific
manner without changes in the expression level of that
TF in the tumor. However, it is likely that increased
levels of a TF in a tumor can result in higher binding at
a partially methylated enhancer, directly leading to loss
of DNA methylation [17]. Based on this secondmechanism, we have attempted to identify TFs that
regulate the target genes of enhancers that are hypo-
methylated in tumors. First, we identified a list of site-
specific TF binding motifs that are enriched within the
enhancers linked to putative target genes. Then, by
examining the expression patterns of each of the TF
family members expected to bind to these motifs, we
have predicted the TF that regulates specific sets of
genes in the different cancer types (Fig. 8). For example,
in bladder cancer (BLCA) we have provided a list of 65,
208, and 65 genes that may be regulated by POU3F1,
FOXA1, or CEBPA, respectively, by binding to a specific
hypomethylated enhancer. In all, utilizing enhancer
methylation patterns, expression of putative target genes,
motif enrichment, and expression of TF family members
that bind to the motif, we have derived a list of 4,280
enhancer-TF-putative target gene linkages.
Some of the cancer type-specific TF networks we show
in Fig. 8 are already known to have a functional role in
the same tumor type, such as PU.1 in AML [59] and
TCF7L2 in colorectal cancer [28, 60–63]. Two of the
four TFs we identified in squamous cell lung cancer
(LUSC), TP63 and SOX2, are oncogenes that are overex-
pressed in LUSC through genomic amplification [64,
65]. Recently, SOX2 and TP63 were shown to interact
functionally and co-localize to a large number of gen-
omic binding sites in squamous cell lung cancer [66]. In
a number of cases, incorporating TF expression data
allowed us to resolve between different members of the
same family that would be indistinguishable by binding
motif alone. For instance, FOXA1 clearly appears to be
responsible for hypomethylation of FOX-containing en-
hancers in breast (BRCA) and bladder (BLCA) cancers,
while FOXA2 appears to be responsible in endometrial
(UCEC). Other TF networks we identified, such as
RUNX1/2 and its association with poor outcome in kid-
ney cancer, have never been reported and will form the
basis for future studies.
The method we describe herein is based on detecting
methylation and expression differences between samples
of the same tumor type, and is therefore aimed at identi-
fying changes that co-occur within particular subsets of
cases. For instance, we found that GATA-containing en-
hancer hypomethylation occurred primarily in the subset
of breast cancer cases belonging to the Luminal subtype,
which also had high expression of the GATA3 gene
(Fig. 6b, c). While GATA3 is a well-studied case, our
method can be applied to identify, understand, and find
biomarkers for novel molecular subtypes. Understanding
the genome-wide transcriptional consequences of mo-
lecular subtypes will be particularly relevant for those
that are defined by genetic mutation of transcriptional
regulators; indeed, transcription factors make up the lar-
gest functional class within the list of 127 cancer genes
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[67]. A number of the altered transcription factor net-
works we identified using ELMER (Fig. 8) were also
present within the 30 or so transcription factors in-
cluded in this TCGA driver gene list. These TFs included
FOXA1, FOXA2, GATA3, NFE2L2, and SOX17. Intri-
guingly, ELMER often identified a particular TF in the
same cancer type or types where it is most frequently
mutated. For instance, FOXA1 is most frequently mu-
tated in Breast and Bladder cancer, and ELMER identi-
fied it in these specific cancers. Likewise, FOXA2 and
SOX17 are primarily mutated in endometrial cancers,
and ELMER identified network alterations specifically in
this cancer type (UCEC). NFE2L2 is most frequently
mutated in lung squamous cell carcinoma (LUSC), the
same cancer type where ELMER detected NFE2L2 alter-
ations. It will take additional work to understand the re-
lationship between genetic mutations of TFs and
epigenetic/transcriptomic changes in each of these dif-
ferent examples, but the identification of important can-
cer driver genes underscores the power of studying
enhancers, which sit at the cis-regulatory interface be-
tween transcription factors, epigenetic modifiers, and
downstream effector genes.
We also note that in some cases, transcription factors
that are not expected to bind to the specific motif being
analyzed were identified as being highly correlated with
the degree of enhancer hypomethylation. In all, we iden-
tified 186 TFs frequently correlated with multiple motifs
that do not correspond to the known motif for that TF
family (Additional file 15). These correlations could be
due to indirect effects caused by TF networks. For ex-
ample, transcription factors regulated by GATA3 may
show a similar correlation of expression with the hypo-
methylated probes in BRCA as does GATA3 itself. An-
other possible cause is suggested by the case of AP-1.
Our results indicate that hypomethylation of AP-1-
containing enhancers is a common feature of many or
most cancer types (including nine of our 10 cancer
types, see Fig. 6a); this confirms our earlier whole-
genome observations in colorectal cancer [21]. While
the AP1 motif is classically described as a binding se-
quence for FOS/JUN dimers, it is found to be enriched
in many ChIP-seq datasets, including those using anti-
bodies that recognize factors other than FOS or JUN
family members [68]. Phosphorylation of JUN can lead
to histone acetylation at AP-1 motif-containing en-
hancers by inhibiting their association with the Mbd3
component of the NuRD complex [69]. This could in
turn allow binding of other positive transcriptional regu-
lators, activation of downstream genes, and a prolifera-
tive expression program. Because JUN activity is
regulated post-transcriptionally, it is logical that our
method (which is based on expression) would miss JUNitself, and instead identify the positive regulators binding
these regions (which are often cell-type specific). For in-
stance, the most strongly associated TF with the AP-1
motif in kidney cancer is RUNX1, while in breast cancer
it is FOXA1, suggesting that many of the AP-1 motif-
containing sites may require AP-1 dependent de-
repression along with positive RUNX1/FOXA activation.
Also included in the list of 186 ‘commonly correlated’
TFs are around 50 zinc finger domain-containing TFs
(known as ZNFs). Although ZNFs are the most abun-
dant class of human site-specific TFs, comprising around
half of all site-specific TFs [70–72], few of them have
been well studied. One of the commonly correlated fac-
tors was ZNF703, which correlated with 16 different mo-
tifs in the BRCA samples. Interestingly, high expression
of ZNF703 has been shown to correlate with poor prog-
nosis in patients with luminal B breast cancer [73]. We
suggest that our analyses can point to a role for other
ZNFs in tumorigenesis. In fact, 11 of the identified ZNFs
showed associations with survival of the cancer in which
they were identified (Additional file 16). For example,
ZNF273 was correlated with four motifs in CRC and
ZNF683 was correlated with nine motifs in KIRC; nei-
ther of these TFs has ever been associated with cancer.
However, there is a strong correlation between high ex-
pression of ZNF273 and ZNF683 with poor survival
rates in colorectal and kidney cancers, respectively. Most
of the time, the 186 ‘commonly correlated’ TFs showed
cancer type-specific correlations. However, one factor
(GRHL2) was identified in the top 1 % of all correlations
for 31 different motifs spread among five of the 10 dif-
ferent cancer types studied. GRHL2 has been shown to
directly bind and activate the hTERT promoter and has
been suggested to be involved in telomerase activation
during cellular immortalization [74]. Perhaps GRHL2
plays an important role in tumor development in many
cancer types.
The results we describe here use motif analysis pri-
marily to help identify the transcription factors respon-
sible for enhancer hypomethylation. However, the most
important output of this work may actually be the iden-
tification of enhancers in which mutations in individual
transcription factor binding sites can be responsible for
cancer risk or cancer progression. A number of studies
have shown that population risk alleles for cancer reside
preferentially in enhancer regions [31, 75–79] and a re-
cent paper demonstrated that these could be identified
in breast cancer by combining DNA methylation and
chromatin conformation capture data to identify puta-
tive enhancers [25]. Somatic enhancer mutations are
predicted to affect cancer progression, although these
have not yet been identified due to the overwhelming
use of exon sequencing as a means to identify new can-
cer mutations. The recent availability of whole-genome
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tion of non-coding mutations, which have been shown
to affect transcription factor binding sites [80–82].
Methods like ELMER, which can identify in vivo enhan-
cer regions in tumors, will be essential for analyzing
non-coding cancer mutations arising from WGS studies.
Conclusions
Although our study is not comprehensive due to the na-
ture of the DNA methylation platform used by TCGA
(which only contains coverage of 15 % of known en-
hancers) and because enhancers have not yet been
mapped in all normal and tumor cell types, our analyses
have allowed us to identify a number of cancer type-
specific transcriptional regulators, along with the cis-
regulatory sequences mediating effects on target genes.
Large-scale identification of such cis-regulatory regions
will be critical for understanding the effects of non-
coding genetic polymorphisms on cancer risk and non-
coding somatic mutations on cancer progression [28, 59,
60]. Complete tumor methylation profiles using whole-
genome bisulfite sequencing [21, 23, 83] are rapidly be-
coming available, and these will dramatically increase
the power of the ELMER approach to reconstruct
complete transcription factor network and identify im-
portant cis-regulatory regions.
Methods
Availability of source code and R package
All source code is available as an R package, ELMER,
downloadable from the main Bioconductor repository
[84] or from our GitHub repository [85]. Vignettes illus-
trating the use of the functions are available as part of
the BioConductor package, along with an example repli-
cating the results described in this paper using the
ELMER function TCGA.pipe. A user manual and tutor-
ial can be downloaded from the GitHub repository here:
[86], and a full manual can be downloaded here: [87].
DNA methylation and RNA-seq datasets
TCGA level 3 DNA methylation data based on the Illu-
mina Infinium HumanMethylation450 BeadArray plat-
form was downloaded from [88]. Only the samples
whitelisted by TCGA for Pan-Cancer Analysis Working
Group were used in the study. The whitelist can be
downloaded from Sage Bionetworks Synapse [89] with
identifier syn1571603. The version numbers and final
sample IDs for each cancer type are listed in Additional
file 1. The DNA methylation level at each CpG is re-
ferred to as a beta (β) value, calculated as (M/(M+U)),
where M represents the methylated allele intensity and
U the unmethylated allele intensity, which are normal-
ized using the TCGA standard pipeline. Beta values are
in the range of 0 to 1, reflecting the fraction ofmethylated alleles at each CpG in the each tumor; beta
values close to 0 indicating low levels of DNA methyla-
tion and beta values close to 1 indicating high levels of
DNA methylation. Since there are no available normal
tissues for acute myeloid leukemia (LAML) and glio-
blastoma multiforme (GBM) in TCGA, we also down-
loaded Infinium HM450K DNA methylation data from
publicly available sources as normal tissue controls for
these two cancer types. A set of 58 sorted glial cell sam-
ples from GEO (accession number GSE41826) was used
as normal reference samples for glioblastoma. A set of
11 sorted blood samples from GEO (accession number
GSE49618) was used for normal reference samples for
leukemia. These data were generated at the USC Epige-
nome Center and were processed through the same data
analysis pipeline that was used to create the TCGA Level
3 data files (all TCGA data were also generated by the
USC Epigenome Center). The sample IDs are also listed
in Additional file 1.
TCGA Level 3 RNA-seq data were downloaded from
[88]. The version number of each package downloaded
is listed in Additional file 1. TCGA uses gene-level ex-
pression values, meaning any alternative isoforms are in-
cluded in a single normalized RSEM expression value.
TCGA data production and analysis pipelines are de-
scribed elsewhere, but a brief description follows: all data
were generated on the Illumina HiSeq platform, with the
exception of UCEC, which was generated on the Illu-
mina GAII platform. Within each cancer type, data were
mapped with MapSplice and quantitated with RSEM
(RNA-seq by Expectation Maximization). RSEM outputs
expression values that are normalized across samples, so
that the third quartile for each sample equals 1,000.
Entrez gene IDs were used for mapping to genomic loca-
tions using GenomicRanges [90]. The final RNA-seq
sample IDs used in our analyses are listed in Additional
file 1.Selecting enhancer probes
Probes overlapping SNPs are removed as part of the
standard TCGA Level 3 pipeline. Probes located less than
2 kb from an annotated transcription start site in GEN-
CODE v.15 were filtered out to remove promoter regions
from our analysis. ENCODE/REMC chromHMM data
were downloaded from [91] and any HM450 probes fall-
ing within the genomic regions annotated as EnhG1,
EnhG2, EnhA1, or EnhA2 were selected. FANTOM5 data
were downloaded from [92] and any HM450 probes fall-
ing within regions annotated as eRNA were selected. This
resulted in 102,518 enhancer probes, which are listed in
Additional file 2. This functionality is implemented in the
get.feature.probe function of the ELMER BioConductor
package.
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methylation changes
Each of the 10 cancer types was processed independently
to identify cancer-specific DNA methylation changes.
For each enhancer probe, we first ranked tumor samples
and normal samples (within the cancer type) by their
DNA methylation beta values. To identify hypomethy-
lated probes, we compared the lower normal quintile
(20 % of normal samples with the lowest methylation)
to the lower tumor quintile (20 % of tumor samples
with the lowest methylation), using an unpaired one-
tailed t-test. Only the lower quintiles were used because
we did not expect all cases to be from a single molecu-
lar subtype, and we sought to identify methylation
changes within cases from the same molecular subtype.
Twenty percent (that is, a quintile) was picked as a cut-
off to include high enough sample numbers to yield t-
test P values that could overcome multiple hypothesis
correction, yet low enough to be able to capture
changes in individual molecular subtypes occurring in
20 % or more of the cases. This number can be set arbi-
trarily as an input to the get.diff.meth function in the
ELMER package, and should be tuned based on sample
sizes in individual studies. The one tailed t-test was
used to rule out the null hypothesis: μtumor ≥ μnormal,
where μtumor is the mean methylation within the lowest
tumor quintile and μnormal is the mean within the low-
est normal quintile. Raw P values were adjusted for
multiple hypothesis testing using the Benjamini-
Hochberg method, and probes were selected when they
had adjusted P value less than 0.01. For additional
stringency, probes were only selected if the methylation
difference |Δ|= |μnormal - μtumor | was greater than 0.3.
This technique is illustrated in Fig. 1b, and carried out
in the get.diff.meth function of the ELMER package.
The same method was used to identify hypermethylated
probes, except we used upper tumor quintile and upper
normal quintile, and chose the opposite tail in the t-
test. The full set of hypermethylated and hypomethy-
lated probes we identified are provided in Additional
file 3, and can be replicated using the TCGA.pipe vi-
gnette in the ELMER package.
Linking enhancer probes with methylation changes to
target genes with expression changes
For additional stringency and to avoid correlations due
to non-cancer contamination, we selected only those en-
hancer probes that had differential methylation as de-
fined above, and where at least 5 % of all samples
(combining tumor and normal) had beta values >0.3.
Then, for each of these differentially methylated enhan-
cer probes, the closest 10 upstream genes and the closest
10 downstream genes were tested for correlation be-
tween methylation of the probe and expression of thegene. To select these genes, the probe-gene distance was
defined as the distance from the probe to a transcription
start site specified by the TCGA RNA-seq Level 3 data
files. We used the Level 3 TCGA RNA-seq data files;
these represent expression at the gene level, and merge
any alternate transcript isoforms into a single expression
value for each gene. Thus, exactly 20 statistical tests
were performed for each probe, as follows. For each
probe-gene pair, the samples (all tumors and normals
within a particular cancer type) were divided into two
groups: the M group, which consisted of the upper
methylation quintile (the 20 % of samples with the high-
est methylation at the enhancer probe), and the U group,
which consisted of the lowest methylation quintile (the
20 % of samples with the lowest methylation.) The 20 %
cutoff is a configurable parameter in the get.pair func-
tion of ELMER. We used 20 % as a balance, which
would allow us to identify changes in a molecular sub-
type making up a minority (that is, 20 %) of cases, while
also yielding enough statistical power to make strong
predictions. For each candidate probe-gene pair, the
Mann-Whitney U test was used to test the null hypoth-
esis that overall gene expression in group M was greater
or equal than that in group U. This non-parametric test
was used in order to minimize the effects of expression
outliers, which can occur across a very wide dynamic
range. For each probe-gene pair tested, the raw P value
Pr was corrected for multiple hypothesis using a permu-
tation approach as follows (implemented in the get.-
permu function of the ELMER package). The gene in the
pair was held constant, and 10,000 random methylation
probes were used to perform the same one-tailed U test,
generating a set of 10,000 permutation P values (Pp). We
chose the 10,000 random probes only from among those
that were ‘distal’ (greater than 2 kb from an annotated
transcription start site), in order to make these null-
model probes qualitatively similar to the probe being
tested. We only used non-enhancer probes, as using en-
hancer probes would introduce large numbers of co-
regulated enhancers. An empirical P value Pe value was
calculated using the following formula (which introduces
a pseudo-count of 1):
Pe ¼ num Pp≤Prð Þ þ 1
10001
ChIA-PET analysis
MCF7 ChIA-PET linkage pairs were taken from a previ-
ous publication [24]. The random pairs were generated
by randomly selecting the same number of probes from
the set of distal enhancer probes, and pairing each with
one or more of the 20 adjacent genes; the number of
links made for each random probe was identical to the
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set has both the same number of probes and the same
number of linked genes as the true set. One hundred
such random datasets were generated to arrive at a 95 %
CI (+/-1.96* SD).
Gene Ontology (GO) enrichment analysis
Genes associated with hypo- or hypermethylated enhan-
cer probes in more than one cancer type were selected
for GO analysis. GO analyses were performed using the
R package ‘topGO’ [93]. The classic Fisher test was used
to generate enrichment P values. To select the GO terms
that pass a significance cutoff, P values were adjusted
using the Benjamini-Hochberg method; only those GO
terms with a P value <0.01 and a fold change >1.5 are
shown in Fig. 5.
Motif analyses
We used FIMO [94] with a P value <1e–4 to scan a +/-
100 bp region around each probe using Factorbook
motif position weight matrices (PWMs) [39, 95] and Jas-
per core human motif PWMs generated from the R
package MotifDb [96]. For each probe set tested (that is,
the list of gene-linked hypomethylated probes in a given
cancer type), a motif enrichment OR and a 95 % CI were


















lower boundary of 95% confidence interval ¼ exp ln ORð Þ−SDð Þ
where a is the number of probes within the selected
probe set that contain one or more motif occurrences; b
is the number of probes within the selected probe set
that do not contain a motif occurrence; c and d are the
same counts within the entire enhancer probe set. A
probe set was considered significantly enriched for a par-
ticular motif if the 95 % CI of the OR was greater than
1.1, and the motif occurred at least 10 times in the probe
set. As described in the text, ORs were also used for rank-
ing candidate motifs. This analysis is implemented in the
get.enrichmed.motifs function of the ELMER package.
Associating TF expression with TF binding motif
methylation
For each motif considered to be enriched within a par-
ticular probe set, we compared the average DNA methy-
lation at all distal enhancer probes within +/− 100bp ofa motif occurrence, to the expression of 1,777 human
TFs ([97] and with further refinements, see Additional
file 17). A statistical test was performed for each motif-
TF pair, as follows. The samples (all tumors and normal
within a particular cancer type) were divided into two
groups: the M group, which consisted of the 20 % of
samples with the highest average methylation at all
motif-adjacent probes, and the U group, which consisted
of the 20 % of samples with the lowest methylation. The
20th percentile cutoff is a parameter to the get.TFs func-
tion of the ELMER package, and was set to allow for
identification of molecular subtypes present in 20 % of
cases. For each candidate motif-TF pair, the Mann-
Whitney U test was used to test the null hypothesis that
overall gene expression in group M was greater or equal
than that in group U. This non-parametric test was used
in order to minimize the effects of expression outliers,
which can occur across a very wide dynamic range. For
each motif tested, this resulted in a raw P value (Pr) for
each of the 1,777 TFs. All TFs were ranked by the
-log10(Pr), and those falling within the top 5 % of this
ranking were considered candidate upstream regulators.
The best upstream TFs for each of these cases was auto-
matically extracted as high-value candidates, and pre-
sented in Fig. 8. These high-value candidates are also
shown in detail in Additional files 9 and 10.
Survival analyses
A Kaplan-Meier survival analysis was used to estimate the
association of the TF expression with the survival of pa-
tients. For each selected TF and cancer type combination,
tumor samples with the highest (top 30 %) and lowest (bot-
tom 30 %) transcription factor expression were analyzed
using a Log Rank test. Overall survival was calculated from
the date of initial diagnosis of cancer to disease-specific
death (patients whose vital status is termed dead) and
months to last follow-up (for patients who are alive).
Data access
The TCGA samples can be downloaded at https://
tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/
anonymous/tumor/. The whitelist from Pan-Can group
is available on Synapse (https://www.synapse.org/) as
syn1571603. The enhancer genomic coordinates can





Additional file 1: TCGA DNA methylation and RNA-seq sample ID
numbers. The data platform and archive version number are listed in the
sheet named ‘Version number’. The ‘DNA methylation sample ID’ sheet
Yao et al. Genome Biology  (2015) 16:105 Page 18 of 21provides information concerning the TCGA sample ID, the tissue type
(normal or tumor), and the cancer type for the DNA methylation
datasets. The ‘RNA-seq sample ID’ sheet provides information concerning
the TCGA sample ID, the tissue type (normal or tumor), and the cancer
type for the RNA-seq datasets.
Additional file 2: Distal enhancer probes on the HM450 array. The
chromosomal location and the name of each of the 102,518 distal
enhancer probes used in this study are indicated.
Additional file 3: Hypo- and hypermethylated enhancer probes
identified for each tumor type. Individual worksheets are provided that
list the hypermethylated probes and hypomethylated probes identified
for each specific cancer type.
Additional file 4: Probe-gene pairs showing inverse correlations
between methylation and expression. Individual worksheets are
provided that list all of the significant probe-gene pairs for hypomethylated
probes and hypermethylated probes in each cancer type. Pr represents real
P value from the Mann-Whitney U test for each pair; Pe represents the
empirical P value for each pair; the distance between the probes and the
putative target genes are shown in the Distance column; the ranking based
on the relative distance of the putative target gene among the 20 adjacent
genes (10 on either side of the enhancer) is shown; and the cancer type
(CT) is indicated. The P value for promoter methylation’ column specifies
the anti correlation between methylation at the promoter itself and the
expression level of the gene. This is calculated using the same Mann-
Whitney statistic we use to evaluate enhancer-expression correlation, but
we average beta values within the standard promoter methylation region,
from -300 to +500 bp relative to the transcription start site (TSS). This region
is consistently methylated in all active promoters based on whole-genome
bisulfite sequencing (in cell lines [95] and primary TCGA tumors, manuscript
in preparation). As with our enhancer method, we select for strong
changes in methylation filtering out any case where 95 % of samples
have methylation less than 0.3; in the spreadsheet, these have a P value
of 1.0. The worksheet ‘tumor vs. normal expression’ contains a table
showing that the majority of target genes linked to hypermethylated
enhancers have lower expression in tumors than normal tissues, while
the majority linked to hypomethylated enhancers have higher expression
in tumors. The worksheet ‘promoter methylation’ shows the fraction of
enhancer-linked genes in each cancer type that also have significant
correlation with methylation of the promoter. It is under 10 % of genes for
all cancer types.
Additional file 5: Quantitative summary of links, probes, and genes
for each cancer type. (A) Shown are histograms representing the
number of putative probes-gene pairs, the number of total probes in the
set of paired-probes, and the number of total genes in the set of paired
probes for the set of hypomethylated (top) and hypermethylated (bottom)
probe-gene pairs in each cancer type. For each plot, the number of probes
identified in one or more tumor types is indicated by the colored bars. (B)
Shown is a heatmap illustrating the similarity of probe-gene pairs, probes in
the pairs, and genes in the pairs among the different cancer types. The color
bar indicates the OR for the similarity (overlap) between the indicated
cancer types (a higher OR indicates a more significant similarity).
Additional file 6: Rank of putative target gene according to
distance in the enhancer-gene pairs for each cancer type. (A) Shown
is the distribution for the ranking (by distance) of each putative target
gene linked to an enhancer for enhancers that are significantly associated
with more than one gene. (B) Shown is the distribution for the ranking
(by distance) of each putative target gene linked to an enhancer for each
cancer type. The left panel shows the pairs for which the enhancer is
significantly associated with more than one gene and the right panel
shows the pairs for which the enhancer is significantly associated with
only one gene.
Additional file 7: Summary of enriched motifs for enhancer-gene
pairs with hypomethylated distal enhancers. On the worksheet
entitled ‘Summary’, the fold enrichment of each indicated motif in a
specific cancer type (CT) is shown. Shown in the Enhancer column is the
number of the paired enhancers (after clustering distal enhancer probes
within 500 bp) containing the enriched motif (the percentage of total
paired hypomethylated enhancers in that cancer type containing eachmotif is shown in parentheses). For each motif, also shown is the number
of genes linked to the probes containing the motif and the number of
probe-gene pairs. The worksheet entitled ‘Detail’ contains information for
each individual probe linked to a putative target gene via a distal region
containing an enriched motif. Pe represents the empirical P value for each
pair; the distance between the probes and the putative target genes are
shown in the Distance column; the ranking based on the relative distance of
the putative target gene among the 20 adjacent genes (10 on either side of
the enhancer) is shown; and the cancer type (CT) is indicated.
Additional file 8: Motif enrichment heatmaps. (A) Shown are the
heatmaps for motifs that are enriched in the sets of all hypomethylated
probes (top panel) and all hypermethylated probes (bottom panel). (B)
Shown are the heatmaps for motifs that are enriched in the sets of only
those hypomethylated (top panel) or hypermethylated (bottom panel)
probes that are linked to putative target genes (B bottom panel).
Additional file 9: Plots of association between all human TFs and
DNA methylation at enriched motif sites. Shown are TF ranking plots
based on the score (-log10(Pr)) of association between TF expression and
DNA methylation of the motif in the cancer type in which the motifs are
enriched. The dashed blue line indicates the boundary of the top 5 %
association score. The top three associated TFs and the TF family
members (dots in red) that are associated with that specific motif are
labeled in the plot.
Additional file 10: Scatter plots for TF family members significantly
associated with DNA methylation at distal enhancer regions having
enriched motifs. Shown are scatter plots for average DNA methylation
at probes having the indicated enriched motif (x axis, shown on the top
of each set of panels) vs. the expression of the significantly correlated
motif-relevant TF family members (y axis, shown on the right side of each
panel). Each dot represents a different patient sample; red and green
indicate the tumor and normal samples, respectively. Pairs that are within
the top 5 % of TFs linked to a given motif are indicated with a number
inside the cell. The number corresponds to the rank of the given TF
relative to all 1,777 TFs (with ‘1’ being the most strongly correlated).
Additional file 11: Survival plots for TF family members
significantly associated with DNA methylation at distal enhancer
regions having enriched motifs. (A) The output of a Cox model
regression analysis for the effects of expression of RUNX1 on survival
within KIRC samples. Leukocyte methylation signature was calculated as
in (PMID 22120008), and staging information was taken from TCGA
clinical data. Leukocyte methylation signature was included to rule out
RUNX1 expression from contaminating leukocytes, which are the main
source of non-cancer cells in KIRC samples. (B) Kaplan-Meier survival
curves for TF family members significantly associated with DNA methyla-
tion at the distal enhancer regions with enriched motifs in the indicated
cancer type. The survival data for patients having tumors with the highest (top
30%) and lowest (bottom 30%) transcription factor expression are shown; the
Log Rank test P value between the high and low groups is indicated.
Additional file 12: Proportion of intragenic vs. intergenic enhancers
that regulate the nearest gene. Shown are bar graphs indicating the
number of intergenic vs. intragenic enhancers, the number of each
category that is associated with expression of the nearest gene, and the
number of intragenic enhancers associated with expression of the nearest
gene with that gene being the one in which the enhancer resides.
Additional file 13: Overlapping analysis between putative probe-
gene pairs in BRCA and interactions from ChIA-PET data from the
MCF7 breast cancer cell line. A list of putative probe-gene pairs in
BRCA that overlap with interactions from ChIA-PET data from the MCF7
cell line is provided. The bar graph shows the comparison of the number
of probe-gene pairs identified within MCF7 ChIA-PET data using the putative
pairs from BRCA vs. random pairs. The random pairs were generated by
randomly selecting the same number of probes from the set of distal
enhancer probes, and pairing each with one or more of the 20 adjacent
genes; the number of links made for each random probe was identical
to the corresponding ‘true’ probe. Thus, the random linkage set has
both the same number of probes and the same number of linked
genes as the true set. One hundred such random datasets were
generated to arrive at a 95 % CI (+/-1.96* SD).
Yao et al. Genome Biology  (2015) 16:105 Page 19 of 21Additional file 14: MYC 3’ end enhancer regulates MYC expression
in colorectal cancer tissue. (A) Shown is a scatter plot showing DNA
methylation at probes located at the 3’ end of the MYC gene vs. the
expression of MYC RNA. Each dot represents a different patient sample;
red and green indicate the tumor and normal samples, respectively. (B)
Shown is the location of the MYC 3’ enhancer and the ENCODE ChIP-seq
histone and transcription factor tracks from the University of California,
Santa Cruz genome browser. The green bar indicates the location of
enhancer that has been previously identified to regulate MYC expression
in the HCT116 colon cancer cell line [57, 58].
Additional file 15: Transcription factors significantly associated
with multiple different motifs. Each row represents individual
transcription factors and each column represent different cancer types.
The numbers in the table show the number of enriched motifs that the
transcription factors associate with in each cancer type; the transcription
factor must be in the top 1 % of all ranked TFs for that specific motif in
that specific cancer type to be listed on the table.
Additional file 16: Survival analysis of commonly identified ZNFs.
(A) Shown is a table listing the subset of ZNFs (the entire list can be
found in Additional file 17) which were identified in the top 1 % of
ranked TFs, which were significantly associated with multiple different
motifs in a specific cancer type (the number of motifs with which the TF
was associated is listed in parentheses), and whose expression level
significantly correlates with patient survival. The direction of correlation is
labeled in column labeled ‘Survival’ (red and green color represents high
expression correlated with worse survival or better bad survival, respectively)
and log Rank test P value between the high and low expression groups is
provided in the column labeled ‘logRankP’. (B) Shown are example Kaplan-
Meier survival curves for two ZNFs. The survival data for patients having
tumors with the highest (top 30 %) and lowest (bottom 30 %) transcription
factor expression is shown; the Log Rank test P value between the high and
low groups is indicated.
Additional file 17: List of the TFs used in this study. Shown is the list
of TFs used to compare expression analysis of all TFs to motif
methylation in the different cancer types, taken from [97].
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